Characterization of novel PI3Kδ inhibitors as potential therapeutics for SLE and lupus nephritis in pre-clinical studies

28Citations
Citations of this article
41Readers
Mendeley users who have this article in their library.

Abstract

SLE is a complex autoimmune inflammatory disease characterized by pathogenic autoantibody production as a consequence of uncontrolled T-B cell activity and immune-complex deposition in various organs, including kidney, leading to tissue damage and function loss. There is a high unmet need for better treatment options other than corticosteroids and immunosuppressants. Phosphoinositol-3 kinase d (PI3Kd) is a promising target in this respect as it is essential in mediating B- and T-cell function in mouse and human. We report the identification of selective PI3Kd inhibitors that blocked B-, T-, and plasmacytoid dendritic cell activities in human peripheral blood and in primary cell co-cultures (BioMAP®) without detecting signs of undesired toxicity. In an IFNa-accelerated mouse SLE model, our PI3Kd inhibitors blocked nephritis development, whether administered at the onset of autoantibody appearance or the onset of proteinuria. Disease amelioration correlated with normalized immune cell numbers in the spleen, reduced immune-complex deposition as well as reduced inflammation, fibrosis, and tissue damage in the kidney. Improvements were similar to those achieved with a frequently prescribed drug for lupus nephritis, the potent immunosuppressant mycophenolate mofetil. Finally, we established a pharmacodynamics/pharmacokinetic/efficacy model that revealed that a sustained PI3Kd inhibition of 50% is sufficient to achieve full efficacy in our disease model. These data demonstrate the therapeutic potential of PI3Kd inhibitors in SLE and lupus nephritis. © 2014 Haselmayer, Camps, Muzerelle, El Bawab, Waltzinger, Bruns, Abla, Polokoff, Jond-Necand, Gaudet, Benoit, Bertschy Meier, Martin, Gretener, Lombardi, Grenningloh, Ladel, Petersen, Gaillard and Ji.

References Powered by Scopus

Mechanisms of disease: Systemic lupus erythematosus

2218Citations
N/AReaders
Get full text

Interferon-inducible gene expression signature in peripheral blood cells of patients with severe lupus

1882Citations
N/AReaders
Get full text

Interferon and granulopoiesis signatures in systemic lupus erythematosus blood

1689Citations
N/AReaders
Get full text

Cited by Powered by Scopus

PI3K inhibitors are finally coming of age

261Citations
N/AReaders
Get full text

PI3K inhibitors in inflammation, autoimmunity and cancer

257Citations
N/AReaders
Get full text

Efficacy and pharmacodynamic modeling of the BTK inhibitor evobrutinib in autoimmune disease models

106Citations
N/AReaders
Get full text

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Cite

CITATION STYLE

APA

Haselmayer, P., Camps, M., Muzerelle, M., Bawab, S. E., Waltzinger, C., Bruns, L., … Ji, H. (2014). Characterization of novel PI3Kδ inhibitors as potential therapeutics for SLE and lupus nephritis in pre-clinical studies. Frontiers in Immunology, 5(MAY). https://doi.org/10.3389/fimmu.2014.00233

Readers' Seniority

Tooltip

Researcher 16

64%

PhD / Post grad / Masters / Doc 9

36%

Readers' Discipline

Tooltip

Agricultural and Biological Sciences 8

33%

Medicine and Dentistry 7

29%

Immunology and Microbiology 5

21%

Biochemistry, Genetics and Molecular Bi... 4

17%

Save time finding and organizing research with Mendeley

Sign up for free